Valuation dashboard for Arcutis Biotherapeutics, Inc. (ARQT) with P/E 153.81, P/B 18.98, EV/EBITDA 94.7 and dividend yield 0.00%. DCF, Graham Number, EPS growth, peer multiples and dividend discount models plus sector comparison against other Healthcare companies.
Arcutis Biotherapeutics, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for a range of skin-related diseases. The company's flagship investigational compound, ARQ-151, a roflumilast cream administered topically, has successfully concluded late-stage clinical development for treating both plaque psoriasis and atopic dermatitis. Beyond its lead asset, Arcutis's pipeline includes several other promising compounds.
Analysis Summary
Trailing-twelve-month margins: gross margin 91.1%, operating margin 7.4%, net margin 6.1%.
At $32.07 (closing price, October 30, 2026), ARQT trades at a P/E of 153.81 and an ROE of 15.05%. Market capitalisation stands at $4.0B.
Balance sheet quality for ARQT: debt-to-equity ratio of 0.52, current ratio of 2.92 over the last 12 months. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| P/E Ratio | 153.81 |
| Price / Book | 18.98 |
| EV / EBITDA | 94.7 |
| Dividend Yield | 0.00% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| ARQT | Arcutis Biotherapeutics, Inc. | $4.0B | 153.81 | 18.98 | 15.1% |
| VRTX | Vertex Pharmaceuticals Incorporated | $141.7B | 32.53 | 7.01 | 23.3% |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $134.0B | 30.25 | 6.57 | 23.3% |
| REGN | Regeneron Pharmaceuticals, Inc. | $95.5B | 20.50 | 2.82 | 15.1% |
| MRNA | Moderna, Inc. | $88.5B | 12.99 | -39.2% | |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $86.5B | 19.22 | 2.62 | 13.8% |
| ARGX | argenx SE | $56.1B | 42.44 | 6.73 | 16.9% |
| 0QNO.L | Lonza Group AG | CHF 43.8B | 5.43 | -1.3% |
Price
| Price | $32.07 (closing price, October 30, 2026) |
| Market Cap | $4.0B |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | 15.05% |
| Return on Invested Capital | 9.95% |
| Return on Assets | 5.84% |
| Gross Margin | 91.14% |
| Operating Margin | 7.38% |
| Net Margin | 6.15% |
Related companies: VRTX · 0QZU.L · REGN · MRNA · 0R2M.L · ARGX · 0QNO.L · RVMD
Explore sector: Healthcare · Biotechnology
More sections of ARQT: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks